With global health funding under unprecedented pressure and WHO's 2035 End TB targets still a distant aspiration for most nations, understanding where tuberculosis burden has shifted — and where it stubbornly hasn't — is one of the most consequential questions in infectious disease epidemiology. This systematic analysis offers the most comprehensive georeferenced accounting of TB's toll to date, arriving at a moment when the data could directly shape resource allocation decisions.
Drawing on the Global Burden of Disease Study 2023 framework, researchers modeled TB incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) across 204 countries and territories from 1990 through 2023. The analysis stratified outcomes by HIV co-infection status and drug-resistance profile — including multidrug-resistant TB — using a population attributable fraction methodology applied to cause-of-death ensemble models fed by vital registration, surveillance, verbal autopsy, and minimally invasive tissue sampling data. Key modifiable risk factors examined include alcohol use, smoking, and elevated fasting plasma glucose, each assessed through a comparative risk assessment framework to quantify their contribution to TB burden.
This study sits at the apex of TB epidemiological science in terms of geographic scope and methodological rigor. The GBD platform's strength lies in synthesizing heterogeneous data sources into comparable estimates, but that same aggregation introduces modeling assumptions that can obscure subnational variation — a critical blind spot when TB burden is hyper-concentrated in specific demographic pockets. The MDR-TB stratification is particularly timely: WHO data have long signaled that drug-resistant strains represent an accelerating share of new cases in Eastern Europe and Central Asia, and this analysis should clarify whether that trend continued through 2023. For HIV-positive populations, TB remains the single largest infectious cause of AIDS-related death, and disaggregation here matters for prioritizing integrated care. The inclusion of metabolic and behavioral risk factors is a welcome evolution — high fasting glucose linking TB to the diabetes epidemic represents an underappreciated intersection. Overall, this is a landmark confirmatory and benchmarking study rather than a paradigm-shifter, but its policy utility is substantial precisely because it establishes a pre-disruption baseline against which future funding cuts can be measured.